Akèy › Nefrit Lupus › Texas
Etid klinik pou Nefrit Lupus nan Texas
12 etid pou Nefrit Lupus ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Sep 14, 2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Baylor College of Medicine Pediatric Immunology Allergy Rheumatology, Houston
Ap rekriteFaz 2
Laj 8 a 20 · Tout sèks · Mizajou Sep 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- The University of Texas Southwestern Medical Center, Dallas
Ap rekriteFaz 2
Laj 12 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT07570862RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Texas Transplant Institute, San Antonio
Ap rekriteFaz 2
Laj 12 a 65 · Tout sèks · Mizajou Aug 24, 2026 · NCT07053800PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Novel Research LLC, Bellaire
- Liberty Research Center, Dallas
- Texas Arthritis Center, El Paso
- ak 5 plis
Ap rekriteFaz 4
Laj 18 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT07611214Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Prolato Clinical Research Center, Houston
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jul 30, 2026 · NCT05268289A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Rheumatology Care Center, PLLC, Bellaire
- Texas Arthritis Center, El Paso
- Novel Research, LLC., Houston
- ak 3 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 30, 2026 · NCT07201129A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- Nkarta Investigational Site, Dallas
- Nkarta Investigational Site, Houston
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 4, 2026 · NCT06557265Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT06434363Lupus Landmark Study: A Prospective Registry and Biorepository
- UT Southwestern Medical Center, Dallas
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
- AARA Clinical Research, Fort Worth
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Nov 6, 2025 · NCT07225387Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.